Drug Information Journal, Vol. 26, pp. VII–XVI, 1992
Printed in the USA. All rights reserved.

0092-8615/92 $5.00 + .00
Copyright © 1992 Drug Information Association Inc.

Contents
Volume 26, 1992

Volume 26, Number 1 January–March, 1992

CONTENTS

Arnold J. Gordon **Robert J. Petrick**	1	Worldwide Regulations for Manufacturers on Clinical Safety Surveillance of Drugs
Phn Nelly Baudrihaye	17	Events and Milestones on the Road to 1992: A View from 1990
Mark Moran	21	Clinical Studies and the Price of Information
Thomas E. Bradstreet et al	31	A Statistics Appreciation Course for Clinical Research Personnel
Sheila R. Shulman **Patricia A. Dicerbo** **Marianne E. Ulcickas** **Louis Lasagna**	41	A Survey of Therapeutic Substitution Programs in Ten Boston Area Hospitals
Gerard W. Wood **Ashok K. Gumbhir** **Johnny L. Anderson** **Shelly C. Anderson**	53	Strategic Planning in the US Pharmaceutical Industry: An Introduction
Gerard W. Wood **Ashok K. Gumbhir** **Johnny L. Anderson** **Shelly C. Anderson**	63	Strategic Planning in the US Pharmaceutical Industry: A National Study
Christy Chuang-Stein	77	Summarizing Laboratory Data with Different Reference Ranges in Multi-Center Clinical Trials
Linda Compton **Cathy Taylor**	85	Current Ethical Issues Surrounding Animal Research
Charles F. Curran **Osman Bawa**	95	Investigational Adverse Reaction Monitoring in a Multinational Pharmaceutical Corporation
Jerry D. Fry **Robert T. Drew**	103	Creation and Implementation of a Computer Validation Program

Ping-Hwa Hsu
Andre G. Pernet
J. Carl Craft
Michael J. Hurley 109 A Method for Identifying Adverse Events Related to New Drug Treatment

Mark E. Sale
Terrence F. Blaschke 119 Incorporating Pharmacokinetic/Pharmacodynamic Modeling in Drug Development – Are We Ready?

Frances O. Kelsey 125 Good Clinical Practices in the US: Impact of European Guidelines

I Software Survey Section: **"Results Master"**

Volume 26, Number 2 April – June, 1992

CONTENTS

Judi Weissinger 133 Carcinogenicity Testing of Therapeutics

Stuart L. Nightingale 141 Unlabeled Uses of Approved Drugs

Rhonda B. Friedman
Kristina L. Baum
Carol Brignoli Gable 149 Rx to OTC Conversions: The Role of Epidemiology

Gary L. Yingling 155 The Impact of Regulatory Issues in Contract Negotiations

Gerald F. Meyer 159 The Food and Drug Administration Perspective on the Importance of Dialogue with Industry

Robert Corak 163 Removing the Mystique Surrounding Optical Disk Technology

David M. Cocchetto
Jon R. Wallace 167 Qualifications of Investigators for Clinical Investigations Conducted Under an IND: A Discussion Paper

Robert J. Petrick
John M. Pakulski
Kathleen Johnson
John L. Hakes 175 The Pfizer International Medical Management System (PIMMS): Tracking Worldwide Registration and Commercialized Products

Rayanne S. Berman 187 Format and Content of a Statistical Data Item

J. K. Haseman 191 Value of Historical Controls in the Interpretation of Rodent Tumor Data

Mark Moran
Suzanne Boots
Nina Resnick
Carl Wallemark 201 The Measurement of Efficiency in Clinical Research and Development

Harold Neal 211 Conduct of Investigator Site Audits in Europe by Clinical Quality Assurance Personnel

Elizabeth A. Chrischilles 219 The Contribution of Epidemiology to Pharmacoeconomic Research

David M. Benjamin 231 When Is a Drug Not a Drug? The L-Tryptophan Tragedy: Lessons to Be Learned

Ji M. Koo
Donald R. Miller 237 North Dakota Pharmacists' Need for Drug Information: 1990 vs 1980

Mark E. Lacy 243 The Systems Approach as a Paradigm for Pharmaceutical Research: A Proposal

Loren L. Miller 251 Pitfalls in the Drug Approval Process: Dose-Effect, Experimental Design, and Risk Benefit Issues

Michael R. Toscani
Gene Resnik 261 Postmarketing Studies: Methods for Implementation and Potential Use of Data

Claude Ameline 267 Opening Remarks—Clinical Trial Supplies

Paul Blattmann 271 Patient Product Information (PPI)—Elements for a Rational Approach

Thomas H. Althuis 279 A Therapeutic and Economic Comparison of the Top Innovative New Drugs of the 1970s and 1980s

Kevin Darryl White
David M. Cocchetto 289 Training and Developing of Clinical Research Personnel Through the Glaxo Professional Development Program

Mark Moran 301 The Relationship of Changes in the Headcount to Go/No Go Decisions

I Software Survey Section

Volume 26, Number 3 July—September, 1992

CONTENTS

Kenneth M. Given 311 Value the US Pharmaceutical Industry Places on Early Dialogue in the Drug Development Process

Henry B. Alsobrook, Jr.	317	An Overview of Liability for OTC Drugs
Peter P. Lamy	329	Heightened Need for Information Exchange in Geriatrics
Noriaki Murao	333	Regulatory Requirements and Practices for Clinical Studies in Japan
Kenneth I. Kaitin **Helen L. Walsh**	341	Are Initiatives to Speed the New Drug Approval Process Working?
Albert Weissman	351	Two Demographic Dichotomies: "Black vs White," "Left vs Right"
Gerald Hajian	361	The Whys and Wherefores of Statistics in Carcinogenicity Testing
Iain J. McGilveray	365	Bioavailability Testing of Medicinal Products and Harmonization of International Testing Requirements and Standards: The Canadian Perspective
Dirk Suwelack **Thomas R. Weihrauch**	371	Practical Issues in Design and Management of Multinational Trials
R. Desgouilles **J. M. Auger** **B. Tisserand** **L. Stéru**	379	A Quantified Internal Audit System Allowing Quality Rating of Clinical Research
Alan Bergelson	389	Clinical Packaging: Adhesives and Inks
James L. Wilder	395	The Strategic Approach to Imaging
Alain Spriet **Thérèse Dupin-Spriet**	405	Good Biometric Practice Proposals for a Set of Procedures
Kevin C. Farmer **Ashok K. Gumbhir**	411	A Historical Perspective of Mergers in the US Pharmaceutical Industry
Barbara A. Edge Padbury	421	When Murphy's Law Runs Rampant
Martin W. Edwards **Stig Jørgenson** **Ivan Jensen**	425	Logistics-Based Approaches to Reducing Clinical Development Times
Lauren D. Harrison **Leocadio V. Lacerna**	433	Reducing Barriers to the Utilization of Literature at Hoffmann-La Roche
L. F. Chasseaud	445	The Importance of Pharmacokinetic/Toxicokinetic and Metabolic Information in Carcinogenicity Study Design

Gustavo Acosta
Nanette E. Holston 457 NDA Day Strategy and Success for ICI Pharmaceuticals Group's DIPRIVAN® (Propofol)

Karl E. Peace 463 The Impact of Investigator Heterogeneity in Clinical Trials on Detecting Treatment Differences

I Software Survey Section

Volume 26, Number 4 October – December, 1992

CONTENTS

Managing Adverse Drug Experience Information

Raymond L. Herman 471 Guest Editor's Note

Christian Bénichou
Gaby Danan 473 EEC Pharmacovigilance and the Pharmaceutical Industry: Common Market, Common Rules?

I. Ralph Edwards 477 The WHO Database – I

I. Ralph Edwards
Marie Lindquist 481 The WHO Database – II

James P. Hickey
Andrew J. Aldridge IV
Dora R. Passino-Reader
Anthony M. Frank 487 An Expert System for Prediction of Chemical Toxicity

Steven S. Rinsler
Richard A. Stein
John A. Harter 497 Predicting Anaphylactoid Reactions Based on COSTART Terms

Michael E. Mabry 505 Computer-Aided Assessment of the Adverse Effects of Antiepileptic Drugs

Max W. Talbott
Ellen Kelso 519 Clinical Trial Adverse Drug Experience Reporting Requirements in the Major Countries and a Simplified Approach Toward Meeting These Requirements

George Phillips 527 The Glaxo International Postmarketing Surveillance System: Present and Future

Elizabeth J. Klinger
Joel A. Riloff
Raymond L. Herman
Gustavo Acosta 537 ARMOR: ICI's Automated Tracking System for Adverse Events from Clinical Trials

Judith A. Sromovsky	545	WAES*Net—Merck's International AE Reporting System
Fred Schneiweiss	549	Issues with Causality Assessment: A Personal Perspective
Joyce M. Johnson	553	Reasonable Possibility: Causality and Postmarketing Surveillance
Leroy C. Knodel	559	Did My Drug Cause This? An Academic Perspective
Mark S. Von Tress	565	Did My Drug Cause This? A Biostatistical Perspective
Arnold J. Gordon	573	An Industry Perspective on the State of Confusion in International ADR Reporting: Current Requirements and Attempts at Standardization
Ronald D. Mann	583	Managing Adverse Reaction Information
Christian Bénichou **Gaby Danan**	589	Causality Assessment in the European Pharmaceutical Industry: Presentation of the Preliminary Results of a New Method
Claudio A. Naranjo **Krista L. Lanctôt**	593	A Consultant's View on the Role of Bayesian Differential Diagnosis in the Safety Assessment of Pharmaceuticals
Jan Venulet	603	The Pharmaceutical Industry on the Continent—A 10-Year Perspective Since Morges

Additional Articles of Significant Interest

David B. Jefferys	609	Good Clinical Practice: EC Expectations Education, Self-Regulation, or Imposition?
Giovanni B. Cassano **Cristina Borghi** **Alberto Petracca** **Bruno M. Cesana** **Martine Garreau** **Ermanno Buratti** **Paolo L. Morselli**	615	The Italian Multicenter Trial on Prevention and Treatment of Benzodiazepine Withdrawal: Methodology and Pretrial
Per Helboe	629	New Designs for Stability Testing Programs: Matrix or Factorial Designs. Authorities' Viewpoint on the Predictive Value of Such Studies
Jürgen Drews	635	Strategies for Successfully Managing Pharmaceutical Research and Development in the 1990s

Thomas J. Hoerger 647 Market Failure, Information Imperfections, and Cost-Effectiveness Analysis

C. A. Teijgeler 655 The Passport to Drug Approval

Ronald Carlisle Hudson 659 Data Management Team-Driven Approach to Handling International Clinical Data

I Software Survey Section: **"Predictor: Laboratory Management System"**

V Volume 26 Contents and Author Index